Abstract
We describe a highly accurate CMB model to predict the therapeutic benefit in prostate cancer patients and uncover the complex interplay between genetic variants and CMBs on NADT resistance. Our model relies only on widely available needle biopsy specimens and provides a robust and cost-effective solution for clinical implementation.
Full Text
Submitted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call